Table 1.
Patient characteristics and outcomes.
| Parameter | Patients |
|---|---|
| Epidemiology | |
| Patients, n | 60 |
| Gender, m/f (%) | 27/33 (45/55) |
| Age, median, range | 52, 18–75 |
| Karnofsky performance score, median, range | 90, 60–90 |
| Numerical Rating Scale (pain measurement), median, range | 0, 0–6 |
| Nutritional Risk Screening 2002, median, range | 1, 0–3 |
| Pathological grading | |
| I n (%) | 4 (6.7) |
| II n (%) | 14 (23.3) |
| III n (%) | 17 (28.4) |
| IV n (%) | 25 (41.6) |
| Tumor position | |
| Left brain, n (%) | 27 (45) |
| Right brain, n (%) | 11 (18.3) |
| Brain stem, n (%) | 9 (15) |
| Other, n (%) | 13 (21.7) |
| IDH-1 status | |
| Mutation, n (%) | 15 (25) |
| Wild type, n (%) | 25 (41.7) |
| Unknown, n (%) | 20 (33.3) |
| Ki-67 expression (cut off rate) | |
| ≤27.5%, n (%) | 28 (46.6) |
| >27.5%, n (%) | 16 (26.7) |
| Unknown, n (%) | 16 (26.7) |
| Diagnostic style | |
| Subtotal resection, n (%) | 20 (33.3) |
| Tumor biopsy, n (%) | 32 (53.4) |
| No biopsy, n (%) | 8 (13.3) |
| Type of therapy | |
| Radiotherapy + TMZ, n (%) | 42 (70) |
| Radiotherapy + TMZ + bevacizumab, n (%) | 10 (16.7) |
| Radiotherapy only, n (%) | 8 (13.3) |
| Follow-up time, median, range | 28.7 (5.4–38.7) |
| Recurrence and/or metastasis at last follow-up | |
| Yes, n (%) | 23 (38.3) |
| No, n (%) | 28 (46.7) |
| Unknown, n (%) | 9 (15) |
| Alive at last follow-up | |
| Yes, n (%) | 38 (63.3) |
| No, n (%) | 22 (36.7) |
| Unknown, n (%) | 0 (0) |